Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years and above~* Gender eligible for study: both~* Hypertensive diabetic patients either previously diagnosed or newly found.~* Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg for newly found hypertensive patients.~* Fasting blood glucose ≥ 126 mg/dl or PP2 blood glucose ≥ 200 mg/dl for newly found diabetes.~* Patients with significant de novo coronary artery disease (diameter stenosis \> 70%) requiring stent implantation (angina pectoris and/or exercise-induced ischemia).~* Patients with informed consent.~Exclusion Criteria:~* Acute ST-segment elevation myocardial infarction (MI), CTO lesions, left main lesions~* Diabetic patients with the use of thiazolidinediones within 3 months~* Previous history of PCI or bypass surgery~* Patients with any contraindications to the treatment of telmisartan or valsartan~* Pregnant or lactating patients~* Chronic alcohol or drug abuse~* Hepatic dysfunction~* Renal dysfunction~* Heart failure (EF \< 50%)~* Expected life expectancy of \< 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).